Clinical trial
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment…
NCT00356122 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00356122 |
|---|---|
| Title | Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase II Multicenter Study of Docetaxel and Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Chemotherapy-Naïve Subjects With Unresectable Locally Advanced and/or Recurrent (Stage IIIB) or Metastatic (Stage IV) Non-Squamous Cell Histology Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Oxaliplatin, Bevacizumab |
| Enrollment | 53 |
| Start date | Jul 1, 2006 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Jul 25, 2006 |
| Last update posted | Oct 17, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: